Germany and USA-based drug discoverer Agennix (FSE: AGX) saw its shares plummet 74% to 0.49 euros after reporting disappointing results from a Phase III trials with its investigational non-small cell lung cancer (NSCLC) drug talactoferrin alfa, calling into question the company’s future, according to analysts at EP Vantage, a unit of EvaluatePharma.
“The swift and steep decline was because this latest failure comes only six months after the drug bombed in sepsis - which had left NSCLC the only development option open to talactoferrin, and Agennix’ only hope of turning its fortunes around,” the analysts commented.
Failed to meet primary endpoint
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze